Abstracts tagged "patient outcomes and remission"

Abstract Number: 1675 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Meenakshi Jolly¹, Hervé Devilliers², Iñigo Rúa-Figueroa³, Desiree R Azizoddin⁴, Raúl Menor Almagro⁵, Francisco Javier López Longo⁶, Juan Gabriel Ovalles-Bonilla⁷, Alejandro Olivé-Marques⁸, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernandez-Nebro¹⁰, Jaime Calvo-Alen¹¹, Txaro García de Vicuña-Pinedo¹², Eva G Tomero-Muriel¹³, Esther Uriarte Isacelaya¹⁴, Angela Pecondon-Español¹⁵, Mercedes Freire-González¹⁶, Ricardo Blanco¹⁷, Marian Gantes Mora¹⁸, Monica Ibanez Barcelo¹⁹, Carlos Alberto Montilla-Morales²⁰, José José C Rosas-Gómez de Salazar²¹, Jesús García-Villanueva²², Paloma Vela-Casasempere²³, María E Ruiz-Lucea²⁴, Francisco J Toyos-Sáenz-de-Miera²⁵, José Hernández Beiraín²⁶, Elvira Diez Alvarez²⁷, Gema Bonilla-Hernán²⁸, Javier Narváez-García²⁹, José Andréu-Sánchez³⁰, Mireia Moreno-Martínez-Losa³¹, Ana Sánchez Atrio³², Maria Loreto Horcada³³, Tatiana Cobo-Ibáñez³⁴, Carlos Marras Fernandez-Cid³⁵, Tomas Ramón Vazquez Rodriguez³⁶, Eva Salgado-Pérez³⁷, Vicente Torrente³⁸, Juan Alegre-Sancho³⁹, Coral Mouriño-Rodriguez⁴⁰, Joel A. Block¹ and JM Pego-Reigosa⁴¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²de médecine Interne, Hôpital Universitaire Dijon, Dijon, France, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Department of Anesthesiology, Stanford University School of Medicine, Palo Alto, CA, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez, Spain, ⁶Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁸Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ¹⁰UGC de Reumatología, Instituto de Investigación Biomédica de Málaga (IBIMA) Hospital Regional Universitario de Málaga Departamento de Medicina y Dermatología, Universidad de Málaga, MÁLAGA, Spain, ¹¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Rheumatology, Hospital de La Princesa. Madrid. Spain, Madrid, Spain, ¹⁴Rheumatology, Hospital Universitario de Donosti, San Sebastian, Spain, ¹⁵Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹⁸Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ¹⁹H. Son Llatzer, Palma de Mallorca, Spain, ²⁰Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ²¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²²HOSPITAL RAMÓN Y CAJAL, Madrid, Spain, ²³Dpt. Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ²⁴Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Complejo Asistencial Universitario de León, León, Spain, ²⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ²⁹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ³⁰HOSPITAL PUERTA DE HIERRO, Madrid, Spain, ³¹HOSPITAL PARC TAULÍ, Barcelona, Spain, ³²University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ³³Rheumatology, Hospital de Navarra, Pamplona, Spain, ³⁴Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³⁵Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ³⁶Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁷COMPLEJO HOSPITALARIO DE OURENSE, Ourense, Spain, ³⁸Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁹HOSPITAL DR. PESET, València, Spain, ⁴⁰Rheumatology, Rheumatology Section, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain, Vigo, Spain, ⁴¹Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Background/Purpose: Remission & Low Disease activity state (LDAS) are the two new health outcome measures developed with “treat to target” strategy in mind for Systemic…
Abstract Number: 2545 • 2016 ACR/ARHP Annual Meeting
Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Linda A. Rasch³, Véronique Lugt¹, Willem F. Lems^1,3, Mike T. Nurmohamed^1,4 and Lilian van Tuyl³, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis…
Abstract Number: 2294 • 2013 ACR/ARHP Annual Meeting
The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic
Maria Dahl Mjaavatten¹, Anne Julsrud Haugen², Halvor Nygaard³, Olav Bjørneboe⁴, Patrik Stolt⁵, Cathrine Thunem⁶ and Tore Kristian Kvien^1,7, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ³Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ⁵Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, ⁶Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ⁷Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: In the ACR/EULAR criteria remission can be defined in two ways, either by fulfilment of 4 Boolean criteria or by a Simplified Disease Activity…
Abstract Number: 2249 • 2013 ACR/ARHP Annual Meeting
What Proportion Of Patients With Rheumatoid Arthritis Fail To Achieve Remission Based On The Patient Global? An Analysis From The Prospective, Observational Biologic Treatment Registry Across Canada
Andrew Chow¹, Philip Baer², William G. Bensen³, Isabelle Fortin⁴, Majed M. Khraishi⁵, Dalton E. Sholter⁶, May Shawi⁷, Allen J. Lehman⁸, Susan M. Otawa⁸, Emmanouil Rampakakis^9,10 and John S. Sampalis^9,10, ¹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁵Nexus Clinical Research, St John's, NF, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁸Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Jewish General Hospital, McGill University, Montreal, QC, Canada
Background/Purpose: According to the latest ACR/EULAR guidelines, Boolean remission in RA is defined as achievement of patient global assessment (PtGA) ≤1, 28-swollen joint count (SJC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].